Asia's largest for-profit healthcare group IHH Healthcare has made a buyout offer to Malaysian-based hospital group Ramsay Sime Darby Health Care (RSDHD) of US$1.35bn.
Multiple sources say US-based buyout specialist KKR is close to closing a deal to buy Spain-based global fertility player IVI-RMA, the largest group in the sector by revenue.
As China's biggest city Shanghai faces a staggered Covid lockdown, HBI catches up with a Chinese healthcare expert who tells us that premium international operators could be significantly hit.
Infermedica, the Polish health tech start-up, will expand its US investments, thanks to the funding gained in a recent Series B financing round. HBI talks with Miłosz Wiciński, Business Development Executive at Infermedica, to learn more.
Europe, with its often rigorous divides between research institutes and university hospitals, has fallen a long way behind power houses such as MIT/Harvard/Mass General in the generation of applied medical science. So how do you build a successful healthcare science cluster in Europe?
As Germany-based healthcare conglomerate Fresenius looks to simplify the group's structure, selling off non-core parts of a business which currently spans hospitals, dialysis, pharma, rehabilitation and more, it is building a $2.4bn new business partnership in the US. We speak to an EU-based source familiar with Fresenius to put this all in context.
At the end of last year, healthcare specialist REIT Icade Santé looked to fall victim to capital markets' apathy for European healthcare services, postponing its IPO. Could it be looking to try again in H2 2022 - or is it too soon to try?
For-profit UK hospital groups are working on their responses to the humanitarian crisis in Ukraine. Circle Health is to sponsor up to 500 work visas for Ukrainian refugees across its 54 sites in the UK. We find out more about the plan, and approach other large providers in the UK to find out what they are doing.
Malaysia and Singapore based Asia-focussed IHH Healthcare’s 2021 results show dynamic growth. Turkish groups are being impacted by the depreciation of the lira, but while revenue from domestic patients in Turkish subsidiary Acibadem shrank between 2017 and 2020, it grew in 2021, up 16.9% year-on-year.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
